专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2016174130A8 CLINICAL GENE SIGNATURE-BASED HUMAN CELL CULTURE MODEL AND USES THEREOF 审中-公开
标题翻译：临床基因特征基于人类细胞培养模型及其用途
公开(公告)号：WO2016174130A8
公开(公告)日：2017-06-15
申请号：PCT/EP2016059477
申请日：2016-04-28
申请人： UNIVERSITÉ DE STRASBOURG , INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE) , INST HOSPITALIER UNIV DE STRASBOURG , ICAHN SCHOOL MED MOUNT SINAI
发明人： BAUMERT THOMAS , HOSHIDA YUJIN
IPC分类号： C12N5/09 , A61K31/00 , A61P1/16 , G01N33/50 , G01N33/574
CPC分类号： C12N5/067 , A61K31/00 , C12N5/0693 , C12N2500/62 , C12N2502/1157 , C12N2502/14 , C12N2503/02 , C12N2506/30 , G01N33/5067 , G01N33/57438 , G01N2800/085
摘要： The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.
摘要翻译：本发明提供了一种简单且稳健的基于人肝细胞的系统，其中持续的丙型肝炎感染，持续的乙型肝炎感染或乙醇暴露诱导临床预后肝脏标志（PLS）高风险基因签名。用于肝细胞癌（HCC）/肝硬化发展和进展的细胞模型系统可以用于筛选用于治疗和/或预防肝硬化和/或HCC以及用于预测肝病的鉴定生物标志物的化合物（尤其是肝硬化）进展和HCC。本发明还涉及使用这种筛选方法已经鉴定的用于治疗和/或预防HCC /肝硬化的特定化合物。

2. 发明申请

WO2015006762A1 METHODS AND COMPOSITIONS FOR EXPANDING LONG-TERM HEMATOPOIETIC STEM CELL POPULATIONS 审中-公开
标题翻译：用于扩展长期HEMATOPOIETIC干细胞群体的方法和组合物
公开(公告)号：WO2015006762A1
公开(公告)日：2015-01-15
申请号：PCT/US2014/046498
申请日：2014-07-14
申请人： THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS , ZHOU, Daohong , LUO, Yi , SHAO, Lijian , FENG, Wei , CHANG, Jianhui
发明人： ZHOU, Daohong , LUO, Yi , SHAO, Lijian , FENG, Wei , CHANG, Jianhui
IPC分类号： A61K35/12 , C12N5/0789 , C12N5/0786
CPC分类号： A61K35/28 , A61K35/15 , A61K2035/124 , C12N5/0647 , C12N2501/2304 , C12N2502/1157 , A61K2300/00
摘要： The invention generally features compositions and methods for expanding long term hematopoietic stem cells (HSCs) in a population of cells. In particular, the invention relates to a method of expanding long term HSCs by culturing an initial population of HSCs with macrophages that promote self-renewal of long term HSCs. The expanded cell population provides a source of cells for therapeutic treatments utilizing HSC transplantation.
摘要翻译：本发明一般具有在细胞群中扩展长期造血干细胞（HSCs）的组合物和方法。特别地，本发明涉及通过培养具有促进长期HSC的自我更新的巨噬细胞的初始HSC群体来扩展长期HSC的方法。扩大的细胞群体提供了使用HSC移植治疗治疗的细胞来源。

3. 发明申请

WO2014102799A1 CD11blow MACROPHAGES AND CONDITIONED MEDIA THEREOF FOR TREATING CANCER AND/OR FIBROSIS 审中-公开
标题翻译： CD11blow用于治疗癌症和/或纤维化的宏观和有条件的媒体
公开(公告)号：WO2014102799A1
公开(公告)日：2014-07-03
申请号：PCT/IL2013/051084
申请日：2013-12-30
申请人： CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD
发明人： BARKAN, Dalit , GILON, Odelya , ARIEL, Amiram , SCHIF-ZUCK, Sagie
IPC分类号： A61K35/12 , C12N5/0786
CPC分类号： A61K35/15 , A61K35/12 , A61K45/06 , C12N5/0645 , C12N5/0656 , C12N2500/70 , C12N2501/15 , C12N2501/58 , C12N2502/00 , C12N2502/1157 , C12N2506/11 , C12N2506/115 , C12N2506/1307
摘要： A conditioned medium of CD11b low macrophages and methods for preparing it are provided. Pharmaceutical compositions comprising the CD11b low macrophages conditioned medium or a culture of CD11b low macrophages and their use in the treatment of cancer or fibrosis are also provided.
摘要翻译：提供了CD11blow巨噬细胞的条件培养基及其制备方法。还提供了包含CD11blow巨噬细胞条件培养基或CD11blow巨噬细胞培养物的药物组合物及其在治疗癌症或纤维化中的用途。

4. 发明申请

WO2013031322A1 三次元共培養モデル及びその使用方法审中-公开
标题翻译：三维共同文化模式及其使用方法
公开(公告)号：WO2013031322A1
公开(公告)日：2013-03-07
申请号：PCT/JP2012/064310
申请日：2012-06-01
申请人：株式会社資生堂 , 松元有羽子 , 加治屋健太朗
发明人：松元　有羽子 , 加治屋　健太朗
IPC分类号： C12N5/078 , C12Q1/02 , C12N15/113
CPC分类号： C12N5/0651 , C12N5/0697 , C12N2502/1157 , C12N2502/1192 , C12N2503/02 , G01N33/5029 , G01N33/5032 , G01N33/5047 , G01N33/5064 , G01N33/5088 , G01N2500/00
摘要：　本発明は、リンパ管内皮細胞、炎症性細胞、及び支持体、を含んで成る三次元モデルであって、当該支持体上に、下から順にリンパ管内皮細胞、炎症性細胞が積層されて成り、当該リンパ管内皮細胞が当該支持体上でリンパ管腔を形成している、三次元モデル及びその使用方法、を提供する。
摘要翻译：本发明提供：包括淋巴内皮细胞，炎症细胞和支持物的三维模型，其中淋巴内皮细胞和炎症细胞以从上至下的顺序层叠在支持体上，并且淋巴内皮细胞形成淋巴管在支架上; 以及利用三维模型的方法。

5. 发明申请

WO2019105864A1 B-CELL CULTIVATION METHOD 审中-公开
公开(公告)号：WO2019105864A1
公开(公告)日：2019-06-06
申请号：PCT/EP2018/082401
申请日：2018-11-23
申请人： F. HOFFMANN-LA ROCHE AG , HOFFMANN-LA ROCHE INC.
发明人： OFFNER, Sonja , JUNG, Friederike
IPC分类号： C12N5/0781 , C07K16/00
CPC分类号： C12N5/0635 , C07K16/00 , C12N2501/2301 , C12N2501/2302 , C12N2501/2304 , C12N2501/2306 , C12N2501/231 , C12N2501/2321 , C12N2501/25 , C12N2502/1114 , C12N2502/1157 , C12N2502/1185 , C12N2529/00
摘要： Herein is reported a method for the co-cultivation of single deposited B-cells, which can be of any source, with EL-4 B5 feeder cells in a suitable co-cultivation medium. In the herein reported methods the EL-4 B5 cells have been irradiated with a dose of less than 40 Gy, preferably 9.5 Gy or less. Thereby the EL-4 B5 cells have a higher viability and maintain the ability to divide in cultivation at doses less than 6 Gy.

6. 发明申请

WO2018134356A1 METHOD FOR PREDICTING THE CLINICAL EVOLUTION OF CANCER PATIENTS 审中-公开
公开(公告)号：WO2018134356A1
公开(公告)日：2018-07-26
申请号：PCT/EP2018/051315
申请日：2018-01-19
申请人： ETABLISSEMENT FRANÇAIS DU SANG , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE HOSPITALIER UNIVERSITAIRE GRENOBLE ALPES , UNIVERSITE GRENOBLE ALPES
发明人： CHAPEROT, Laurence , CHARLES, Julie , PLUMAS, Joel , ASPORD, Caroline
IPC分类号： C12Q1/68
CPC分类号： C12N5/0639 , C12N5/0638 , C12N2502/1157 , C12N2502/30 , C12N2503/00
摘要： The invention pertains to an in vitro method for predicting the clinical evolution of a patient suffering from cancer, said method comprising the steps of: a) obtaining a plasmacytoid dendritic cell (pDC) line pulsed with at least one tumoral antigen, and irradiated; said pDC line sharing at least one major histocompatibility complex (MHC) allele with PBMC from the patient suffering from cancer; b) bringing the pulsed and irradiated pDC line obtained at step a) into contact with PBMC from the patient suffering from cancer, and co-culturing the pulsed and irradiated pDC line and the PBMC; c) bringing the pulsed and irradiated pDC line obtained at step a) again into contact with the co-culture obtained at step b), and co-culturing the pulsed and irradiated pDC line and the co-culture obtained at step b) to obtain stimulated T cells; d) measuring the avidity of the stimulated T cells obtained at step c) for the at least one tumoral antigen; and e) predicting the clinical evolution of the patient suffering from cancer based on the comparison of the avidity measured at step d) to a reference level.

7. 发明申请

WO2012026687A2 세포응집을 이용한 인간 혈액 유래 혈구 세포괴의 유도와 이를 이용한 혈중 성체줄기세포 및 전구세포의 증폭방법 및 상기의 방법에 의해 제조된 줄기세포 审中-公开
标题翻译：使用细胞凝血的人血液衍生的血液细胞质量测定，使用其的血液成熟干细胞，扩增祖细胞的方法和使用该方法产生的干细胞
公开(公告)号：WO2012026687A2
公开(公告)日：2012-03-01
申请号：PCT/KR2011/005762
申请日：2011-08-08
申请人： 서울대학교산학협력단 , 박영배 , 김효수 , 강현재 , 조현재 , 허진 , 박종한 , 장재희
发明人： 박영배 , 김효수 , 강현재 , 조현재 , 허진 , 박종한 , 장재희
IPC分类号： C12N5/0789 , C12N5/0786 , C12N5/02
CPC分类号： C12N5/0647 , C12N5/0634 , C12N2502/1157 , C12N2513/00
摘要： 본 발명은 혈액에 미량으로만 존재하는 혈중 성체줄기세포 및 전구세포들을 혈액 단핵구 세포를 이용하여 효과적으로 배양, 증식시킴으로써 효율적으로 대량 확보하는 기술에 관한 것이다. 본 발명에 따르면, 줄기세포를 혈액에서 미량으로 채취할 수밖에 없었던 한계를 극복할 수 있으며, 줄기세포의 다능성을 쉽게 확보할 수 있다.
摘要翻译：本发明涉及使用单核细胞血液细胞有效培养和增殖血液成体干细胞和仅存在少量的祖细胞以有效获得大量干细胞的技术。根据本发明，可以克服仅能从血液中获得少量干细胞的限制，并且可以容易地获得干细胞的多能性。

8. 发明申请

WO2011099783A3 METHOD FOR PRODUCING CELL GROWTH FACTORS FROM ADIPOSE-DERIVED STEM CELLS AND MONOCYTES AND APPLICATIONS THEREOF 审中-公开
标题翻译：用于从ADIOSE衍生的干细胞和单核细胞生产细胞生长因子的方法及其应用
公开(公告)号：WO2011099783A3
公开(公告)日：2012-01-12
申请号：PCT/KR2011000885
申请日：2011-02-10
申请人： HERSHE BIO INC , JUNG YOUNG CHOON , HONG YOUNG SIL
发明人： JUNG YOUNG CHOON , HONG YOUNG SIL
IPC分类号： C12N5/0775 , A61P37/06 , C07K14/475 , C12N5/02
CPC分类号： C12N5/0667 , A61K2035/124 , C12N2500/90 , C12N2502/1157
摘要： The present invention relates to cell growth factors from adipose-derived stem cells and monocytes; and more specifically, to a preparation method of a culture for the adipose-derived stem cells, comprising: (a) culturing adipose-derived stem cells from a stromal vascular fraction (SVF); (b) mixing the adipose-derived stem cells with monocytes and culturing in a serum-free medium; and (c) isolating the culture of the cells and floats from the cell culture medium. Compared to the single culture of adipose-derived stem cells, the culture according to the present invention makes it possible to obtain a high concentration of cell growth factors from a mixed culture of adipose-derived stem cells and monocytes. As such, the equivalent effects such as the tissue generation induced by the cells can be achieved, and any side effects associated with the onset of a tumor that can be caused by the direct administration of adipose-derived stem cells can be avoided, thereby making the present invention method useful for the preparation of a composition for use in tissue generation and skin improvement.
摘要翻译：本发明涉及来自脂肪来源的干细胞和单核细胞的细胞生长因子; 更具体地说，涉及一种用于脂肪来源的干细胞培养的制备方法，包括：（a）从基质血管部分（SVF）培养来自脂肪的干细胞; （b）将来自脂肪的干细胞与单核细胞混合并在无血清培养基中培养; 和（c）从细胞培养基中分离细胞和浮游物的培养物。与脂肪来源的干细胞的单一培养物相比，本发明的培养物可以从脂肪来源的干细胞和单核细胞的混合培养物中获得高浓度的细胞生长因子。因此，可以实现诸如由细胞诱导的组织产生的等效的效果，并且可以避免与直接施用脂肪来源的干细胞可引起的与肿瘤发作相关的任何副作用，从而使本发明的方法可用于制备用于组织产生和皮肤改善的组合物。

9. 发明申请

WO2011099783A2 지방조직 유래 줄기세포 및 단핵구로부터 세포성장인자의 생산방법 및 그 이용 审中-公开
标题翻译：从脂肪组织干细胞和单核细胞制备细胞生长因子的方法及其应用
公开(公告)号：WO2011099783A2
公开(公告)日：2011-08-18
申请号：PCT/KR2011/000885
申请日：2011-02-10
申请人： 허쉬바이오주식회사 , 정영춘 , 홍영실
发明人： 정영춘 , 홍영실
IPC分类号： C12N5/0775 , C12N5/02 , C07K14/475 , A61P37/06
CPC分类号： C12N5/0667 , A61K2035/124 , C12N2500/90 , C12N2502/1157
摘要： 본 발명은 지방조직 유래 줄기세포 및 단핵구로부터 세포성장인자에 관한 것으로, 보다 상세하게는, 본 발명은 (a) 지방조직 유래의 세포분획(Stromal Vascular Fraction, SVF)으로부터 지방유래 줄기세포를 배양하는 단계; (b) 상기 지방유래 줄기세포에 단핵구를 혼합하여 무혈청 배지에서 배양하는 단계; 및 (c) 상기 세포 배양액에서 세포 및 부유물을 배양물만을 수득하는 단계를 포함하는 지방조직 유래 줄기세포의 배양물을 제조하는 방법에 관한 것이다. 본 발명에 따른 배양물은 지방조직 유래 줄기세포를 단독으로 배양에 의한 것보다, 지방조직 유래 줄기세포 및 단핵구의 혼합배양으로부터 고농도의 성장인자가 함유된 배양물을 수득할 수 있기 때문에, 상기 세포에 의한 조직재생 등과 동일한 효과를 얻을 수 있고, 지방조직 유래 줄기세포를 신체에 직접 투여함으로써 야기될 수 있는 종양발생 관련 부작용을 방지할 수 있으므로, 이를 이용한 조직재생 및 피부개선 조성물의 제조에 유용하다.
摘要翻译：
本发明涉及一种细胞生长因子从派生脂肪组织的干细胞和单核细胞，并且更具体地，本发明为（a）衍生自脂肪组织的细胞级分（基质血管组分，SVF）培养脂肪干细胞; （b）通过混合单核细胞在无血清培养基中培养所述脂肪来源的干细胞; 并且（c）仅从细胞培养液中获得细胞和悬浮液的培养物。由于根据本发明的培养是为了获得含有生长因子的高浓度从混合培养物比从单独培养的脂肪组织来源的干细胞，脂肪组织来源的干细胞，和单核细胞，该细胞得到的培养也能够得到与通过，所以能够防止肿瘤相关的副作用可通过在体内的脂肪组织来源的干细胞的直接给药而引起的组织相同的效果，它是用于生产组织，并使用相同的皮肤改善组合物是有用的。。

10. 发明申请

WO2016178514A1 조혈모세포의 세포주기를 조절하는 KAI1 단백질 및 이의 용도 审中-公开
标题翻译： KAL1蛋白质控制HEMATOPOIETIC干细胞的细胞周期及其用途
公开(公告)号：WO2016178514A1
公开(公告)日：2016-11-10
申请号：PCT/KR2016/004707
申请日：2016-05-04
申请人： 서울대학교 산학협력단
发明人： 김효수 , 허진 , 최재일 , 강진아 , 남브니엘
IPC分类号： A61K38/17 , C12N5/0789 , C07K14/705 , A61K35/28
CPC分类号： A61K35/28 , A61K38/17 , A61K2035/124 , A61P35/00 , C07K14/705 , C12N5/0081 , C12N5/0634 , C12N2502/1157 , C12N2502/1171
摘要： 본 발명은 조혈모세포의 세포주기를 조절하는 KAI1 단백질 및 이의 용도에 관한 것으로서, 보다 구체적으로는 KAI1(CD82) 폴리펩타이드 또는 이를 코딩하는 유전자를 포함하는 조혈모세포의 세포 주기 조절용 조성물, 또는 혈액 종양 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명에 따르면, KAI1(CD82)이 조혈모세포의 Hierarchy 중 가장 최상위의 조혈모세포(LT-HSC)에만 발현하고, 상기 KAI1을 이용하여 LT-HSC를 순도 높게 얻을 수 있는바, LT-HSC만을 순도 높게 이식함으로써 조혈모세포 이식의 다양한 부작용을 억제 할 수 있다. 또한, KAI1이 LT-HSC의 Quiescence(정지)에 중요하게 작용하며, LT-HSC의 Quiescence을 유지함으로써 다양한 Stress(5-FU, Irradiation)에 의한 세포 손상에 대해 저항성을 가지는바, 상기 세포를 이용하여 세포뱅크를 만들고 세포이식을 통한 혈액종양 세포치료제로 사용될 수 있을 것으로 기대된다.
摘要翻译：本发明涉及一种控制造血干细胞的细胞周期的KAl1蛋白及其用途，更具体地，涉及一种包含KA1（CD82）多肽或编码其的基因的组合物，用于控制造血干细胞的细胞周期细胞或用于预防或治疗血液肿瘤的药物组合物。在本发明中，KA1（CD82）仅在作为造血干细胞层次上的最上层干细胞的造血干细胞（LT-HSC）中表达，可以使用KAl1获得高纯度的LT-HSC，因此可以通过仅移植高纯度的LT-HSC来抑制造血干细胞移植的各种副作用。此外，KAl1重要地作用于LT-HSC的静止，并且通过维持LT-HSC的静止由于各种应力（5-FU，照射）具有抗细胞损伤。因此，预期该细胞可用于制造细胞库，并且可以通过细胞移植用作血液肿瘤细胞治疗产品。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式